Schering-Plough’s social conscience
Ethical practices in sales, marketing, clinical research and supplier management is one tenet of Schering-Plough's "long-term plan to identify and address broad societal issues," company says May 19. Considered part of the firm's strategic business process, the plan will address topics such as patient safety, diversity within the company, human rights, security, occupational health safety and the environment. Company also cites "access to medicines for patients who are indigent, disadvantaged or among the working poor" as a priority under the strategy. Schering recently announced it will proceed with a plan to provide free drugs to low-income Medicare beneficiaries who are enrolled in Part D, as well as those who are not (1"The Pink Sheet" April 24, 2006, p. 10)...
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.